Compare CXAI & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CXAI | GRML |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8M | 29.2M |
| IPO Year | 2020 | 2022 |
| Metric | CXAI | GRML |
|---|---|---|
| Price | $2.94 | $3.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.4M | ★ 5.4M |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.25 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,583,000.00 | N/A |
| Revenue This Year | $33.54 | N/A |
| Revenue Next Year | $116.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.09 | $0.16 |
| 52 Week High | $4.88 | $11.66 |
| Indicator | CXAI | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 57.66 | 54.37 |
| Support Level | $0.20 | $0.20 |
| Resistance Level | $4.88 | $11.66 |
| Average True Range (ATR) | 0.30 | 0.71 |
| MACD | -0.17 | -0.16 |
| Stochastic Oscillator | 5.60 | 31.97 |
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. Its cloud-based, mobile-first platform integrates artificial intelligence, automation, and real-time analytics to streamline workplace interactions across people, spaces, and technology. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, Agentic AI Capabilities, and CXAI-VU. The company generates the majority of its revenue from Licenses.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.